Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIB Study to Assess the Efficacy of GSK 249553 as Adjuvant Therapy Given to MAGE-3-Positive Patients With Non-Small-Cell Lung Cancer in Stage IB (T2/N0) or II (T1/N1 or T2/N1 or T3/N0), Who Have Had Complete Surgical Resection
Brief Summary: Patients will receive injections of GSK 249553 vaccine . Appropriate tests will be performed to assess the safety of the treatment and its ability to induce an immune response.


Options:
A: Arm Label: Investigational Arm; Type: EXPERIMENTAL; Interventions: Biological: Tecemotide, Drug: Single low dose cyclophosphamide, Other: Best Supportive Care (BSC) | Arm Label: Control Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Other: Saline, Other: Best Supportive Care (BSC) | Intervention Type: BIOLOGICAL; Name: Tecemotide; Assigned to Arm(s): Investigational Arm | Intervention Type: DRUG; Name: Single low dose cyclophosphamide; Assigned to Arm(s): Investigational Arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Control Arm | Intervention Type: OTHER; Name: Saline; Assigned to Arm(s): Control Arm | Intervention Type: OTHER; Name: Best Supportive Care (BSC); Assigned to Arm(s): Control Arm, Investigational Arm
B: Arm Label: GSK 249553 Group; Type: EXPERIMENTAL; Interventions: Biological: GSK 249553 vaccine | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: GSK 249553 vaccine; Assigned to Arm(s): GSK 249553 Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group
C: Arm Label: GSK1572932 Group; Type: EXPERIMENTAL; Interventions: Biological: GSK1572932A Antigen-Specific Cancer Immunotherapeutic | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo Control | Intervention Type: BIOLOGICAL; Name: GSK1572932A Antigen-Specific Cancer Immunotherapeutic; Assigned to Arm(s): GSK1572932 Group | Intervention Type: BIOLOGICAL; Name: Placebo Control; Assigned to Arm(s): Placebo Group
D: Arm Label: 60 Gy RT; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Radiation: 60 Gy RT | Arm Label: 74 Gy RT; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Radiation: 74 Gy RT | Arm Label: 60 Gy RT + Cetuximab; Type: EXPERIMENTAL; Interventions: Biological: Cetuximab, Drug: Carboplatin, Drug: Paclitaxel, Radiation: 60 Gy RT | Arm Label: 74 Gy RT + Cetuximab; Type: EXPERIMENTAL; Interventions: Biological: Cetuximab, Drug: Carboplatin, Drug: Paclitaxel, Radiation: 74 Gy RT | Intervention Type: BIOLOGICAL; Name: Cetuximab; Assigned to Arm(s): 60 Gy RT + Cetuximab, 74 Gy RT + Cetuximab | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): 60 Gy RT, 60 Gy RT + Cetuximab, 74 Gy RT, 74 Gy RT + Cetuximab | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): 60 Gy RT, 60 Gy RT + Cetuximab, 74 Gy RT, 74 Gy RT + Cetuximab | Intervention Type: RADIATION; Name: 60 Gy RT; Assigned to Arm(s): 60 Gy RT, 60 Gy RT + Cetuximab | Intervention Type: RADIATION; Name: 74 Gy RT; Assigned to Arm(s): 74 Gy RT, 74 Gy RT + Cetuximab

Answer: B